查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1962139

全球數位生物標記市場規模、佔有率、趨勢和成長分析報告（2026-2034）

Global Digital Biomarkers Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 178 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

數位生物標記市場預計將從 2025 年的 58.3 億美元成長到 2034 年的 372.9 億美元，2026 年至 2034 年的複合年成長率為 22.91%。

在技​​術進步的推動下，數位生物標記市場正迅速擴張，這些進步催生了用於健康監測和疾病管理的創新解決方案。數位生物標記是指透過數位設備收集的客觀、可量化的生理和行為數據，它正在改變醫療服務提供者評估患者健康狀況和治療效果的方式。透過利用穿戴式裝置、行動應用程式和遠端監測工具，醫療專業人員可以即時了解患者​​的病情，從而提供更個人化和主動的護理。

此外，將人工智慧 (AI) 和機器學習技術融入數位生物標記分析，正在提升這些工具的準確性和預測能力。人工智慧演算法能夠分析大量數據，識別傳統方法無法發現的模式和關聯性，從而實現更早發現健康問題並採取更有效的干涉措施。這種向數據驅動型醫療保健的轉變，賦予了患者在自身健康管理中更積極主動的角色，並促進了他們參與治療方案並堅持治療。

此外，人們對預防醫學和慢性病管理的日益關注也推動了對數位生物標記的需求。隨著全球醫療系統努力降低成本並改善治療效果，遠端、持續監測健康指標的能力變得愈發重要。數位生物標記有助於及時干預、減少住院次數並提高患者的整體生活品質。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球數位生物標記市場：按類型分類

  • 市場分析、洞察與預測
  • 穿戴式裝置
  • 基於行動裝置的應用程式
  • 感應器
  • 其他

第5章 全球數位生物標記市場：依臨床實務分類

  • 市場分析、洞察與預測
  • 用於診斷的數位生物標記
  • 數位生物標記的監測
  • 預測性和預後性數位生物標記物
  • 其他

第6章 全球數位生物標記市場：依治療領域分類

  • 市場分析、洞察與預測
  • 心血管和代謝疾病（CVMD）
  • 呼吸系統疾病
  • 精神疾病
  • 睡眠/運動障礙
  • 神經系統疾病
  • 肌肉骨骼疾病
  • 其他

第7章 全球數位生物標記市場：依最終用途分類

  • 市場分析、洞察與預測
  • 醫療保健公司
  • 醫療服務提供方
  • 付款人
  • 其他

第8章 全球數位生物標記市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第9章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第10章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Amgen Inc
    • Biogen Inc
    • ActiGraph LLC
    • AliveCor Inc
    • Empatica Inc
    • IXICO Plc
    • Neurotrack Technologies Inc
    • Clario
    • Koneksa
    • Huma
    • Sonde Health Inc
    • Aural Analytics
    • Adherium Limited
    • Imagene AI
    • Brainomix
簡介目錄
Product Code: VMR112111961

The Digital Biomarkers Market size is expected to reach USD 37.29 Billion in 2034 from USD 5.83 Billion (2025) growing at a CAGR of 22.91% during 2026-2034.

The Digital Biomarkers Market is rapidly expanding as advancements in technology enable the development of innovative solutions for health monitoring and disease management. Digital biomarkers, which are objective, quantifiable physiological and behavioral data collected through digital devices, are transforming how healthcare providers assess patient health and treatment efficacy. By leveraging wearables, mobile applications, and remote monitoring tools, healthcare professionals can gain real-time insights into patient conditions, leading to more personalized and proactive care.

Moreover, the integration of artificial intelligence and machine learning into digital biomarker analysis is enhancing the accuracy and predictive capabilities of these tools. AI algorithms can analyze vast amounts of data to identify patterns and correlations that may not be apparent through traditional methods, enabling earlier detection of health issues and more effective interventions. This shift towards data-driven healthcare is empowering patients to take an active role in managing their health, fostering greater engagement and adherence to treatment plans.

Additionally, the growing emphasis on preventive healthcare and chronic disease management is driving demand for digital biomarkers. As healthcare systems worldwide seek to reduce costs and improve outcomes, the ability to monitor health metrics remotely and continuously is becoming increasingly valuable. Digital biomarkers can facilitate timely interventions, reduce hospitalizations, and enhance overall patient quality of life.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

  • Wearable
  • Mobile Based Applications
  • Sensors
  • Others

By Clinical Practice

  • Diagnostic Digital Biomarkers
  • Monitoring Digital Biomarkers
  • Predictive And Prognostic Digital Biomarkers
  • Others

By Therapeutic Area

  • Cardiovascular And Metabolic Disorders (CVMD)
  • Respiratory Disorders
  • Psychiatric Disorders
  • Sleep & Movement Disease
  • Neurological Disorders
  • Musculoskeletal Disorders
  • Others

By End-Use Outlook

  • Healthcare Companies
  • Healthcare Providers
  • Payers
  • Others

COMPANIES PROFILED

  • Amgen Inc, Biogen Inc, ActiGraph LLC, AliveCor Inc, Empatica Inc, IXICO plc, Neurotrack Technologies Inc, Clario, Koneksa, Huma, Sonde Health Inc, Aural Analytics, Adherium Limited, Imagene AI, Brainomix

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL DIGITAL BIOMARKERS MARKET: BY TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Type
  • 4.2. Wearable Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Mobile Based Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Sensors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL DIGITAL BIOMARKERS MARKET: BY CLINICAL PRACTICE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Clinical Practice
  • 5.2. Diagnostic Digital Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Monitoring Digital Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Predictive And Prognostic Digital Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL DIGITAL BIOMARKERS MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Therapeutic Area
  • 6.2. Cardiovascular And Metabolic Disorders (CVMD) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Respiratory Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Psychiatric Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Sleep & Movement Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.6. Neurological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.7. Musculoskeletal Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL DIGITAL BIOMARKERS MARKET: BY END-USE OUTLOOK 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast End-use Outlook
  • 7.2. Healthcare Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Healthcare Providers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Payers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL DIGITAL BIOMARKERS MARKET: BY REGION 2022-2034(USD MN)

  • 8.1. Regional Outlook
  • 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.2.1 By Type
    • 8.2.2 By Clinical Practice
    • 8.2.3 By Therapeutic Area
    • 8.2.4 By End-use Outlook
    • 8.2.5 United States
    • 8.2.6 Canada
    • 8.2.7 Mexico
  • 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.3.1 By Type
    • 8.3.2 By Clinical Practice
    • 8.3.3 By Therapeutic Area
    • 8.3.4 By End-use Outlook
    • 8.3.5 United Kingdom
    • 8.3.6 France
    • 8.3.7 Germany
    • 8.3.8 Italy
    • 8.3.9 Russia
    • 8.3.10 Rest Of Europe
  • 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.4.1 By Type
    • 8.4.2 By Clinical Practice
    • 8.4.3 By Therapeutic Area
    • 8.4.4 By End-use Outlook
    • 8.4.5 India
    • 8.4.6 Japan
    • 8.4.7 South Korea
    • 8.4.8 Australia
    • 8.4.9 South East Asia
    • 8.4.10 Rest Of Asia Pacific
  • 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.5.1 By Type
    • 8.5.2 By Clinical Practice
    • 8.5.3 By Therapeutic Area
    • 8.5.4 By End-use Outlook
    • 8.5.5 Brazil
    • 8.5.6 Argentina
    • 8.5.7 Peru
    • 8.5.8 Chile
    • 8.5.9 South East Asia
    • 8.5.10 Rest of Latin America
  • 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.6.1 By Type
    • 8.6.2 By Clinical Practice
    • 8.6.3 By Therapeutic Area
    • 8.6.4 By End-use Outlook
    • 8.6.5 Saudi Arabia
    • 8.6.6 UAE
    • 8.6.7 Israel
    • 8.6.8 South Africa
    • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

  • 9.1. Recent Developments
  • 9.2. Company Categorization
  • 9.3. Supply Chain & Channel Partners (based on availability)
  • 9.4. Market Share & Positioning Analysis (based on availability)
  • 9.5. Vendor Landscape (based on availability)
  • 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL DIGITAL BIOMARKERS INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Company Profiles
    • 10.2.1 Amgen Inc
    • 10.2.2 Biogen Inc
    • 10.2.3 ActiGraph LLC
    • 10.2.4 AliveCor Inc
    • 10.2.5 Empatica Inc
    • 10.2.6 IXICO Plc
    • 10.2.7 Neurotrack Technologies Inc
    • 10.2.8 Clario
    • 10.2.9 Koneksa
    • 10.2.10 Huma
    • 10.2.11 Sonde Health Inc
    • 10.2.12 Aural Analytics
    • 10.2.13 Adherium Limited
    • 10.2.14 Imagene AI
    • 10.2.15 Brainomix